Overview


According to FutureWise analysis, the market for Alpha Thalassemia is expected to grow at a CAGR of 10.70% over the forecast period of 2023-2031.

Alpha thalassemia is a genetic blood disorder characterized by a reduced production of alpha globin chains, which are essential components of hemoglobin, the protein responsible for providing oxygen in red blood cells. The condition primarily affects individuals of Asian, African, and Mediterranean descent. The severity of alpha thalassemia can vary depending on the number of affected alpha globin genes, leading to different forms of the disorder.

Different forms of alpha thalassemia can manifest depending on the number of affected alpha globin genes. In the silent carrier form, individuals have one affected alpha globin gene and one normal gene, resulting in no noticeable symptoms and a normal life expectancy. Alpha thalassemia trait (minor) occurs when individuals inherit two affected alpha globin genes, leading to mild anemia, but they generally lead normal lives without requiring treatment. Hemoglobin H (HbH) disease arises when three out of four alpha globin genes are affected, causing moderate to severe hemolytic anemia that requires medical management. The most severe form, hemoglobin Bart's hydrops fetalis, occurs when all four alpha globin genes are affected, leading to the formation of abnormal hemoglobin during fetal development, and is usually fatal before or shortly after birth. Management strategies vary depending on the severity, and ongoing research aims to enhance the quality of life for those affected by alpha thalassemia, while genetic counseling plays a crucial role in guiding families with a history of the disorder.

FutureWise Market Research has published a report that provides an insightful analysis of alpha thalassemia market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry.

According to the analysis conducted by FutureWise research analysts, the alpha thalassemia market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Pharmaceuticals Inc
  • Alnylam Pharmaceuticals Inc
  • Calimmune Inc
  • CRISPR Therapeutics
  • Editas Medicine Inc
  • Errant Gene Therapeutics LLC
  • Gamida Cell Ltd
  • Gilead Sciences Inc
  • Incyte Corp
  • Ionis Pharmaceuticals Inc
  • IRBM Science Park SpA
  • Johnson and Johnson
  • Kiadis Pharma NV
  • La Jolla Pharmaceutical Company
  • Merck and Co Inc
  • PharmaEssentia Corp
  • Protagonist Therapeutics Inc
  • Sangamo Therapeutics Inc
  • Zydus Cadila Healthcare Ltd.

(Note: The list of the major players will be updated with the latest market scenario and trends)

The increasing prevalence of genetic disorders, advancements in healthcare technologies and treatments, rising funding for research and development, and the growing expenditure on healthcare by individuals are expected to propel the Alpha Thalassemia Market. The rising awareness and early detection of alpha thalassemia also contribute to the market's growth. As healthcare systems improve and screening programs become more accessible, more cases of alpha thalassemia are being identified at an early stage. Early diagnosis allows for timely intervention and medical management to enhance the quality of life for affected individuals. Additionally, the supportive role of patient advocacy groups and initiatives by governments and non-profit organizations to raise awareness about rare genetic disorders like alpha thalassemia contribute to market growth. These efforts help to educate the public and healthcare professionals about the condition, leading to improved diagnosis rates and better access to resources and support for affected individuals and their families. Moreover, researchers and pharmaceutical companies are continuously working to develop innovative treatment options, including gene therapy and targeted therapies, to address the underlying genetic mutations and improve the management of alpha thalassemia. These efforts are expected to create opportunities for market players to enhance their customer base resulting in target market growth. However, alpha thalassemia is considered a rare genetic disorder, which may pose challenges in terms of research funding and conducting large-scale clinical trials. The relatively small patient population may hinder the development of new treatments and therapies specifically tailored to alpha thalassemia, which is expected to hinder market growth.

By Type

  • Hb Bart syndrome
  • HbH disease
  • Silent Carrier State
  • Trait

By Diagnosis

  • Perinatal Testing
    • Complete Blood Count (CBC)
    • DNA testing
  • Prenatal Testing
    • Prenatal Genetic Testing
    • Chorionic Villus Sampling
  • Pre-Implantation

By Treatment

  • Blood Transfusions
  • Iron Chelation
  • Bone Marrow
  • Stem Cell Transplant
  • Surgery
  • Gene Therapy

By End-User

  • Hospitals
  • Biotechnological laboratories
  • Diagnostic Laboratories
  • Educational Research Institutes
  • Pharmaceutical Industries
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. The presence of major players, the high frequency of thalassemia patients in the area, and the developed healthcare infrastructure are some of the major reasons responsible for the market's growth. In addition, favourable government efforts and a rise in research collaboration numbers are anticipated to fuel market expansion. Due to a rise in public awareness of the disorder, an increase in the population of people carrying the thalassemia gene, and an increase in birth rates brought on by population genetic diversity, the United States holds the largest percentage of the market. 

  • Tier 1 players-established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Alpha Thalassemia Market By Type, By Diagnosis, By Treatment, By End-user, and By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections which are represented in the format of data-sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. 
  • To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization services offered are free of charge with purchase of any license of the report.
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Alpha Thalassemia Market Variables, Trends and Scope
    •        1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Treatment Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Alpha Thalassemia Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Alpha Thalassemia Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Treatment Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Treatment Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Alpha Thalassemia Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hb Bart syndrome
        2. HbH disease
        3. Silent Carrier State
        4. Trait

  • 8.   Global Alpha Thalassemia Market, By Diagnosis Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Perinatal Testing
         1.1. Blood Count (CBC)
         1.2. DNA testing
        2. Prenatal Testing
         2.1. Prenatal Genetic Testing
         2.2. Chorionic Villus Sampling
        3. Pre-Implantation

  • 9.   Global Alpha Thalassemia Market, By Treatment Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Blood Transfusions
        2. Iron Chelation
        3. Bone Marrow
        4. Stem Cell Transplant
        5. Surgery and
        6. Gene Therapy

  • 10.   Global Alpha Thalassemia Market, By End-User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals,
        2. Biotechnological laboratories
        3. Diagnostic Laboratories
        4. Educational Research Institutes
        5. Pharmaceutical Industries
        6. Others

  • 11.   North America Alpha Thalassemia Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Alpha Thalassemia Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Alpha Thalassemia Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Alpha Thalassemia Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Alpha Thalassemia Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Types Offered and Financial Layouts)
    •   1. Pharmaceuticals Inc
         1.1. Company Overview
         1.2. Type Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Alnylam Pharmaceuticals Inc
         2.1. Company Overview
         2.2. Type Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Calimmune Inc
         3.1. Company Overview
         3.2. Type Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. PathoFinder BV
         4.1. Company Overview
         4.2. Type Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Editas Medicine Inc
         5.1. Company Overview
         5.2. Type Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Errant Gene Therapeutics LLC
         6.1. Company Overview
         6.2. Type Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Gamida Cell Ltd
         7.1. Company Overview
         7.2. Type Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Gilead Sciences Inc
         8.1. Company Overview
         8.2. Type Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Incyte Corp
         9.1. Company Overview
         9.2. Type Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Ionis Pharmaceuticals Inc
         10.1. Company Overview
         10.2. Type Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. IRBM Science Park SpA
         11.1. Company Overview
         11.2. Type Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Johnson and Johnson
         12.1. Company Overview
         12.2. Type Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Kiadis Pharma NV
         13.1. Company Overview
         13.2. Type Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. La Jolla Pharmaceutical Company
         14.1. Company Overview
         14.2. Type Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Merck and Co Inc
         15.1. Company Overview
         15.2. Type Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. PharmaEssentia Corp
         16.1. Company Overview
         16.2. Type Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. Protagonist Therapeutics Inc
         17.1. Company Overview
         17.2. Type Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
        18. Sangamo Therapeutics Inc
         18.1. Company Overview
         18.2. Type Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview
        19. Zydus Cadila Healthcare Ltd.
         19.1. Company Overview
         19.2. Type Portfolio
         19.3. SWOT Analysis
         19.4. Financial Overview
         19.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 19.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients